Literature DB >> 34034779

Involvement of TLR4 signaling regulated-COX2/PGE2 axis in liver fibrosis induced by Schistosoma japonicum infection.

Lan Chen1, Xiaofang Ji1, Manni Wang1, Xiaoyan Liao1, Cuiying Liang1, Juanjuan Tang1, Zhencheng Wen1, Ferrandon Dominique1,2, Zi Li3.   

Abstract

BACKGROUND: Hepatic stellate cell (HSC) activation plays a pivotal role in hepatic inflammation and liver fibrosis. TLR4 pathway activation has been reported to be involved in mice liver fibrosis induced by hepatitis virus infection, alcohol abuse, biliary ligation, carbon tetrachloride 4 treatment, and Schistosoma japonicum (Sj) infection. The effect and mechanisms of the cyclooxygenase 2 (COX2)/prostanoid E2 (PGE2) axis on liver fibrosis induced by Sj are still unclear.
METHODS: Mice liver fibrosis were induced by cutaneous infection of Sj cercariae. COX-2 inhibitor, NS398 were injected from week 5 to week 7, while TLR4 inhibitor TAK242 were injected from week 4 to week 8 post Sj infection. Human HSCs line, LX-2 cells were cultured and exposed to LPS or synthetic PGE2, or pretreated by TAK242, TLR4-siRNA or NS398. Liver tissue and serum or in vitro cultured cell lysaste were collected at indicated time courses for exploring the relationship between TLR4 and COX2-PGE2 axis through qPCR, western blot, immunohistochemical assay, ect. One-way analysis of variance among multiple groups followed by Uncorrected Fisher's LSD-t test or paired comparisons through t test were performed to tell the statistical differences.
RESULTS: This study investigated the link between the COX2/PGE2 axis and TLR4 signaling in the induction of liver fibrogenesis in mice during Sj infection and in vitro culture of HSC strain-LX-2. The COX2/PGE2 axis was positively associated with Sj-induced liver fibrosis. TLR4 pathway activation stimulated the COX2/PGE2 axis in Sj-infected mice and in lipopolysaccharide (LPS)-exposed cultured HSCs. Synthetic PGE2 activated cultured HSCs through upregulation of alpha smooth muscle actin (α-SMA) expression. In LPS-triggered HSCs, NS398, a COX2 inhibitor, led to suppression of PGE2 synthesis and reduced expression of α-SMA and type I collagen (COL I).
CONCLUSIONS: These results indicate firstly the positive association of the COX2/PGE2 axis with liver fibrosis induced by Sj infection. TLR4 signaling may at least partially control the COX2/PGE2 axis in Sj-infected mice liver and in vitro cultured HSCs. The COX2/PGE2-EP2/EP4 axis might be a good drug target against liver fibrosis induced by Sj infection.

Entities:  

Keywords:  COX2/PGE2 axis; Liver fibrosis; Schistosoma japonicum; TLR4 signaling

Year:  2021        PMID: 34034779     DOI: 10.1186/s13071-021-04790-7

Source DB:  PubMed          Journal:  Parasit Vectors        ISSN: 1756-3305            Impact factor:   3.876


  35 in total

1.  Inhibition of cyclooxygenase-2 alleviates liver cirrhosis via improvement of the dysfunctional gut-liver axis in rats.

Authors:  Jin-Hang Gao; Shi-Lei Wen; Huan Tong; Chun-Hui Wang; Wen-Juan Yang; Shi-Hang Tang; Zhao-Ping Yan; Yang Tai; Cheng Ye; Rui Liu; Zhi-Yin Huang; Ying-Mei Tang; Jin-Hui Yang; Cheng-Wei Tang
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-04-07       Impact factor: 4.052

Review 2.  Multifaceted roles of PGE2 in inflammation and cancer.

Authors:  Masako Nakanishi; Daniel W Rosenberg
Journal:  Semin Immunopathol       Date:  2012-09-21       Impact factor: 9.623

3.  Agonist-specific regulation of monocyte chemoattractant protein-1 expression by cyclooxygenase metabolites in hepatic stellate cells.

Authors:  E Efsen; A Bonacchi; S Pastacaldi; A J Valente; U O Wenzel; C Tosti-Guerra; M Pinzani; G Laffi; H E Abboud; P Gentilini; F Marra
Journal:  Hepatology       Date:  2001-03       Impact factor: 17.425

Review 4.  Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection.

Authors:  Jianxiong Jiang; Ray Dingledine
Journal:  Trends Pharmacol Sci       Date:  2013-06-21       Impact factor: 14.819

5.  Inhibition of the expression of alpha-smooth muscle actin in human hepatic stellate cell line, LI90, by a selective cyclooxygenase 2 inhibitor, NS-398.

Authors:  Jidong Cheng; Hiroyasu Imanishi; Weidong Liu; Atara Iwasaki; Noboru Ueki; Hideji Nakamura; Toshikazu Hada
Journal:  Biochem Biophys Res Commun       Date:  2002-10-11       Impact factor: 3.575

6.  The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation.

Authors:  Anna Planagumà; Joan Clària; Rosa Miquel; Marta López-Parra; Esther Titos; Jaime L Masferrer; Vicente Arroyo; Joan Rodés
Journal:  FASEB J       Date:  2005-05-04       Impact factor: 5.191

7.  Role of NF-kappaB in the antiproliferative effect of endothelin-1 and tumor necrosis factor-alpha in human hepatic stellate cells. Involvement of cyclooxygenase-2.

Authors:  C Gallois; A Habib; J Tao; S Moulin; J Maclouf; A Mallat; S Lotersztajn
Journal:  J Biol Chem       Date:  1998-09-04       Impact factor: 5.157

Review 8.  Prostaglandin E2-induced inflammation: Relevance of prostaglandin E receptors.

Authors:  Kohichi Kawahara; Hirofumi Hohjoh; Tomoaki Inazumi; Soken Tsuchiya; Yukihiko Sugimoto
Journal:  Biochim Biophys Acta       Date:  2014-07-17

9.  JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis1.

Authors:  Hirofumi Yamamoto; Motoi Kondo; Shoji Nakamori; Hiroaki Nagano; Ken-Ichi Wakasa; Yurika Sugita; Jin Chang-De; Shogo Kobayashi; Bazarragchaa Damdinsuren; Keizo Dono; Koji Umeshita; Mitsugu Sekimoto; Masato Sakon; Nariaki Matsuura; Morito Monden
Journal:  Gastroenterology       Date:  2003-08       Impact factor: 22.682

10.  Celecoxib induces hepatic stellate cell apoptosis through inhibition of Akt activation and suppresses hepatic fibrosis in rats.

Authors:  Y-H Paik; J K Kim; J I Lee; S H Kang; D Y Kim; S H An; S J Lee; D K Lee; K-H Han; C Y Chon; S I Lee; K S Lee; D A Brenner
Journal:  Gut       Date:  2009-02-06       Impact factor: 23.059

View more
  6 in total

1.  [Therapeutic mechanism of the Mongolian medicine Qiwei Qinggan Powder against liver fibrosis based on UHPLC-TOF-MS combined with network pharmacological methods].

Authors:  C Zhang; Y Yan; X Gao; Y Ma
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-08-20

2.  Interaction between COX-2 and ER stress is involved in the apoptosis-induced myocardial ischemia/reperfusion injury.

Authors:  Wenhui Tao; Lingui Li; Junkai Hu; Shangxian Xu; Biying Wang; Jun Ding; Mian Zhang; Xiaowen Meng; Xiang Wei; Xisheng Shan; Ke Peng; Huayue Liu; Fuhai Ji
Journal:  Am J Transl Res       Date:  2022-05-15       Impact factor: 3.940

3.  Interleukin-33 deficiency prevents biliary injuries and repairments caused by Clonorchis sinensis via restraining type 2 cytokines.

Authors:  Chao Yan; Na Xu; Man Liu; Zhihua Jiang; Jing Wu; Stephane Koda; Yu Chen; Beibei Zhang; Qian Yu; Yin-Hai Xu; Jian-Lin Wu; Kui-Yang Zheng
Journal:  Parasit Vectors       Date:  2022-10-22       Impact factor: 4.047

4.  Tumor protein P63 Regulated 1 contributes to inflammation and cell proliferation of cystitis glandularis through regulating the NF-кB/cyclooxygenase-2/prostaglandin E2 axis.

Authors:  Tao Hong; Songzhe Piao; Liangxue Sun; Yiran Tao; Mang Ke
Journal:  Bosn J Basic Med Sci       Date:  2022-02-01       Impact factor: 3.363

5.  Inhibition of COX-2 ameliorates murine liver schistosomiasis japonica through splenic cellular immunoregulation.

Authors:  Zhang Qi; Chen Lan; Ji Xiaofang; Tang Juanjuan; Fu Cheng; Huang Ting; Shen Erxia; Li Zi
Journal:  Parasit Vectors       Date:  2022-04-23       Impact factor: 4.047

6.  Novel pyrrolopyrimidine derivatives: design, synthesis, molecular docking, molecular simulations and biological evaluations as antioxidant and anti-inflammatory agents.

Authors:  Amira I Sayed; Yara E Mansour; Mohamed A Ali; Omnia Aly; Zainab M Khoder; Ahmed M Said; Samar S Fatahala; Rania H Abd El-Hameed
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.